Get the Stockscreener App
0.6803
2.18%
0.0145
After Hours:
.68
-0.0003
-0.04%
Cytosorbents Corp stock is traded at $0.6803, with a volume of 63,230.
It is up +2.18% in the last 24 hours and down -6.82% over the past month.
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
See More
Previous Close:
$0.6658
Open:
$0.68
24h Volume:
63,230
Relative Volume:
0.56
Market Cap:
$42.73M
Revenue:
$33.79M
Net Income/Loss:
$-18.67M
P/E Ratio:
-1.8992
EPS:
-0.3582
Net Cash Flow:
$-19.17M
1W Performance:
+5.93%
1M Performance:
-6.82%
6M Performance:
-37.59%
1Y Performance:
-34.59%
1-Day Range:
$0.6614
$0.6997
1-Week Range:
$0.616
$0.6997
52-Week Range:
$0.60
$1.61
Cytosorbents Corp Stock (CTSO) Company Profile
Name
Cytosorbents Corp
Sector
Industry
Phone
973-329-8885
Address
305 COLLEGE ROAD EAST, PRINCETON, NJ
Compare CTSO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTSO
Cytosorbents Corp
|
0.6803 | 41.82M | 33.79M | -18.67M | -19.17M | -0.3582 |
|
ABT
Abbott Laboratories
|
127.78 | 219.88B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
97.79 | 141.54B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
366.39 | 133.39B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
100.31 | 124.82B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
85.85 | 48.84B | 5.88B | 1.34B | 799.60M | 2.3489 |
Cytosorbents Corp Stock (CTSO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-07-23 | Initiated | B. Riley Securities | Buy |
| Oct-14-21 | Resumed | B. Riley Securities | Buy |
| Sep-17-20 | Initiated | Jefferies | Buy |
| Sep-01-20 | Initiated | SVB Leerink | Outperform |
| Aug-08-17 | Reiterated | Maxim Group | Buy |
| Oct-26-16 | Initiated | Aegis Capital | Buy |
| May-24-16 | Initiated | Maxim Group | Buy |
| Oct-29-15 | Upgrade | WBB Securities | Speculative Buy → Buy |
| May-12-15 | Reiterated | MLV & Co | Buy |
| Apr-01-15 | Reiterated | MLV & Co | Buy |
| Mar-05-15 | Initiated | MLV & Co | Buy |
| Feb-25-15 | Initiated | WBB Securities | Speculative Buy |
| Jan-27-15 | Reiterated | H.C. Wainwright | Buy |
View All
Cytosorbents Corp Stock (CTSO) Latest News
Can Cytosorbents Corporation stock deliver sustainable ROE2025 Market Overview & Long-Term Investment Growth Plans - bolumsonucanavari.com
What is the fair value of Cytosorbents Corporation stock now2025 Technical Overview & Daily Volume Surge Trade Alerts - Улправда
Can Cytosorbents Corporation stock rebound after recent weakness2025 Biggest Moves & Risk Managed Investment Strategies - Улправда
Cytosorbents (NASDAQ:CTSO) Receives “Buy” Rating from D. Boral Capital - Defense World
CTSO: D. Boral Capital Reaffirms Buy Rating and $10 Price Target - GuruFocus
CytoSorbents to Participate in a Virtual Fireside Chat with D. Boral Capital on Monday, December 15, 2025 - PR Newswire
CytoSorbents (NASDAQ: CTSO) to review $37.0M sales, DrugSorb-ATR in Dec. 15 virtual fireside chat - Stock Titan
Cytosorbents (NASDAQ:CTSO) & BioLife Solutions (NASDAQ:BLFS) Financial Comparison - Defense World
How analysts rate Cytosorbents Corporation stock todayPortfolio Update Summary & Safe Capital Investment Plans - Newser
Can Cytosorbents Corporation (HQE1) stock sustain double digit ROEJuly 2025 Recap & Long-Term Safe Investment Ideas - Newser
What technical patterns form on Cytosorbents Corporation (HQE1) stock chartsVolume Spike & Real-Time Stock Price Movement Reports - Newser
CytoSorbents (CTSO) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
How Cytosorbents Corporation stock performs in rising dollar environmentEarnings Performance Report & Verified Short-Term Plans - Newser
Is Cytosorbents Corporation a good long term investmentVolume Profile Analysis & Free Unlock Exclusive Strategies - earlytimes.in
An analyst sees good growth prospects for Cytosorbents Corp (CTSO) - Setenews
CytoSorbents reports Q3 adjusted EPS (4c), consensus (5c) - MSN
CEO Chan Buys 100,000 ($64K) Of CytoSorbents Corp [CTSO] - TradingView
Cytosorbents Corp’s Earnings Call: Growth Amid Challenges - MSN
How Cytosorbents Corporation (HQE1) stock responds to bond marketJuly 2025 Outlook & Real-Time Stock Price Movement Reports - newser.com
CTSO CEO Phillip Chan boosts stake with 100,000-share purchase - Stock Titan
Zacks Small Cap Weighs in on Cytosorbents Q1 Earnings - Defense World
Will Cytosorbents Corporation (HQE1) stock remain on Wall Street radarBull Run & Reliable Volume Spike Trade Alerts - newser.com
How buyback programs support Cytosorbents Corporation (HQE1) stockStock Surge & AI Driven Price Predictions - newser.com
CytoSorbents at Jefferies London: Strategic Growth and Regulatory Pathways - Investing.com
Is Cytosorbents Corporation (HQE1) stock a top pick for value investorsBuy Signal & Consistent Return Investment Signals - newser.com
Combining price and volume data for Cytosorbents CorporationJuly 2025 Trade Ideas & Fast Moving Stock Trade Plans - newser.com
Will Cytosorbents Corporation (HQE1) stock benefit from Fed rate cutsForecast Cut & Weekly Consistent Profit Watchlists - newser.com
Updated: CytoSorbents to Present at the Jefferies Global Healthcare Conference in London – Company Announcement - Financial Times
Cytosorbents’ (CTSO) Buy Rating Reiterated at D. Boral Capital - Defense World
CytoSorbents (NASDAQ: CTSO) to present at Jefferies Healthcare Conference in London - Stock Titan
HC Wainwright Cuts Cytosorbents (NASDAQ:CTSO) Price Target to $0.75 - Defense World
Published on: 2025-11-16 10:30:06 - newser.com
Using Python tools to backtest Cytosorbents Corporation strategiesMarket Performance Report & Weekly Breakout Opportunity Watchlist - newser.com
CytoSorbents price target lowered to 75c from $1 at H.C. Wainwright - MSN
Will Cytosorbents Corporation stock recover faster than marketMarket Volume Report & Free Community Consensus Stock Picks - newser.com
Will breakout in Cytosorbents Corporation lead to full recoveryGap Up & Free Fast Entry Momentum Trade Alerts - newser.com
CytoSorbents implemented workforce and cost reduction program - MSN
Published on: 2025-11-15 12:38:52 - newser.com
Can machine learning forecast Cytosorbents Corporation recoveryTrade Ideas & Weekly Breakout Opportunity Watchlist - newser.com
Cytosorbents Corporation (HQE1.F) Stock Price, News, Quote & History - Yahoo! Finance Canada
CTSO: Analyst Maintains Buy Rating with Steady Price Target of $10.00 | CTSO Stock News - GuruFocus
CytoSorbents Grew Its Sales But Just Missed Profit Targets - Finimize
CTSO Analyst Rating Update: HC Wainwright Lowers Price Target | - GuruFocus
Cytosorbents Corporation (NASDAQ:CTSO) Q3 2025 Earnings Call Transcript - Insider Monkey
CytoSorbents: Q3 Earnings Snapshot - Connecticut Post
Cytosorbents Corp Stock (CTSO) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):